Canada Cybin acquires license for psychedelic molecules from Mindset Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward Rowan DunneSeptember 27, 2022
Canada PsyCan pushes federal policy-makers to lift restrictions on psychedelics Non-profit says Canada needs to make room for healthcare innovation with respect to psychedelic therapies Rowan DunneSeptember 21, 2022
Canada Numinus launches ketamine-assisted therapy in Toronto Neurology Centre of Toronto in Forest Hill expands its therapy catalogue Rowan DunneSeptember 21, 2022
Psychedelics MindMed doses first patient with MDMA-like compounds in new trial New study will compare the effects of MDA and MDMA in humans for the first time Rowan DunneSeptember 20, 2022
Canada ATMA receives Health Canada approval for new psilocybin trial Study will evaluate psilocybin efficacy in healthcare workers with mental health challenges related to pandemic Rowan DunneSeptember 15, 2022
Canada DOSED 2 screening sells out at Vancouver’s Rio Theatre Film screening was followed by audience Q&A session hosted by director Rowan DunneSeptember 13, 2022
Canada Algernon receives approval to conduct DMT study in the Netherlands New clinical research will assess efficacy of IV formulation for the treatment of strokes Rowan DunneSeptember 12, 2022
Canada Optimi makes history with gargantuan psilocybin harvest Company believes it has completed the largest mushroom harvest Canada has ever seen Rowan DunneSeptember 9, 2022
News Psilocybin more efficient for rumination than common antidepressant: study The study assessed differences between psilocybin and escitalopram on common signs in MDD Natalia Buendia CalvilloSeptember 9, 2022
Psychedelics Xtalks to host upcoming webinar on psychedelic know-how Free virtual conference will discuss unique requisites of psychedelic clinical development Rowan DunneSeptember 7, 2022